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Background: Macrolide antibiotics are increasingly prescribed for subjects with non-cystic
fibrosis (CF) bronchiectasis, an empiric extension of their proven efficacy in CF. Widespread,
injudicious use of long-acting macrolides, particularly azithromycin, risks significantly
increasing population antimicrobial resistance.
Methods: In an attempt to power a definitive randomised-controlled trial (RCT), an uncon-
trolled evaluation of the impact of long-term, low-dose oral erythromycin therapy upon pulmo-
nary exacerbation frequency in non-CF bronchiectasis subjects was performed. Adult
bronchiectasis subjects with at least 2 infective exacerbations in the preceding 12 months
were followed for 12 months following commencement of prophylactic oral erythromycin
250 mgs daily. The co-primary outcome measures, comparing the 12 month erythromycin
and pre-erythomycin periods, were numbers of infective exacerbations and days of antibiotic
therapy for infective exacerbations.
Results: In the 24 evaluable subjects completing a minimum of 12 months of therapy, erythro-
mycin was associated with halving of both the median (range) annual number of infective exacer-
bations (2 (0e8) vs 4 (2e11), 95% CI 1.5 to 3.5, p < 0.0001) and annual days of antibiotic use (21
(0e78) vs 44 (15e138), 95% CI 18 to 40, p< 0.0001) comparedwith the preceding 12month period.
Conclusions: Low-dose erythromycin may have a robust effect upon exacerbation frequency in
non-CF bronchiectasis subjects with frequent exacerbations and this warrants proceeding to
a definitive intervention study. These data have enabled powering of an RCT of long-term, low-
dose erythromycin, which is now underway and also incorporates bronchoscopic evaluation for
pathophysiologic data.
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Bronchiectasis and low-dose erythromycin 947Non-cystic fibrosis (CF) bronchiectasis has failed to attract disease with the potential to result in death in the subse-
the profile and research expenditure of its more fashion-
able cousin, CF and much of the therapy employed for
subjects with bronchiectasis is simply extrapolated from CF
management. However, where randomised-controlled trials
of proven CF therapies have been conducted in bronchi-
ectasis subjects, they have shown negative, even delete-
rious, results.1e3 Azithromycin is increasingly being used
empirically in the management of bronchiectasis in the
clinic with open-label studies suggesting benefit.4e6
However, there are significant risks associated with more
widespread use of long-acting macrolides,7 particularly
antimicrobial resistance. Azithromycin persists at subin-
hibitory concentrations for prolonged periods (up to 30
days8) and has the propensity to rapidly induce antibiotic
resistance (potentially to b-lactams in addition to macro-
lides).9 A single 3 day course of azithromycin increases the
proportion of macrolide-resistant streptococci by up to 53%
compared with placebo9 and the increasing prevalence of
macrolide-resistant Streptococcus pneumoniae strains in
Portugal has been linked to increasing azithromycin
prescription between 1999 and 2002.10 The establishment
of azithromycin therapy for non-CF bronchiectasis has the
very real potential to be empirically extended even further
into widespread chronic maintenance therapy for patient
with ‘chronic lung conditions’, with substantial risks to
population antimicrobial resistance. Erythromycin poten-
tially offers macrolide immunomodulatory benefits with
a lower risk of resistance induction11 and one prior study in
bronchiectasis adults has shown improvements in sputum
volume and lung function.12
In order to obtain powering data for an RCT of long-
term, low-dose erythromycin therapy, we evaluated the
effects of open-label erythromycin upon exacerbation
frequency and antibiotic use in frequent ‘exacerbators’
with non-CF bronchiectasis.
Subjects were recruited from the Respiratory Medicine
Department of the MaterAdult Hospital, a tertiary metro-
politan teaching hospital that also includes the regional
adult CF unit. Subjects aged 25 to 85 years had a diagnosis
of bronchiectasis confirmed on high-resolution computed
tomographic (HRCT) scan of the chest, had daily chronic
sputum production, had experienced a minimum of 2
infective pulmonary exacerbations requiring antibiotic
therapy in the preceding 12 months and had no treatable
cause for recurrent exacerbations. Exclusion criteria
included current smoking, macrolide therapy within the
prior 3 months, culture of mycobacterial organisms,
concomitant medications with the substantial for important
interactions with erythromycin and any non-respiratoryTable 1 Comparison of outcomes in the pre-erythromycin and
Pre-erythromycin
Total antibiotic courses 4 (2e11)
Total days of antibiotics 44 (15e138)
Intravenous courses of antibiotics 0 (0e3)
Oral courses of antibiotics 3 (1e11)
FEV1 (SD) 1.67 (0.72)
(Data are presented as median (range) unless otherwise indicated; *
commencement of erythromycin).quent 12 months. Initiation or cessation of respiratory
medications during the 12 month treatment period resulted
in exclusion of data.
Subjects were commenced upon 250 mgs daily of eryth-
romycin base (given as 400 mgs of erythromycin ethyl-
succinate), reviewed 1 month after commencement and
then at intervals according to clinical need for the remainder
of the 12 month period. The co-primary outcome measures
were the number of pulmonary exacerbations requiring
antibiotics (both oral and intravenous) per patient per year
and the total days of antibiotics per person per year,
comparing the 12 months of erythromycin therapy with the
immediately preceding 12 month period. Patients’ reported
rescue antibiotic use was independently verified for all
subjects by obtaining and reviewing pharmacy and medica-
tion prescription records from both the hospital pharmacy
and patients’ private pharmacies. Only subjects completing
at least 12months of uninterrupted therapywere included in
the per protocol analysis. Data were analysed using Wilcox-
on’s signed ranks test and measures of effect are reported
with 95% confidence intervals (CI).
Twenty-nine (29) subjects commenced long-term eryth-
romycin therapy however one subject died (severe chronic
hypercapneoic respiratory failure at enrolment and died of
progressive respiratory failure, after 6 months), one subject
was non-compliant, two subjects withdrew (one developed
nausea, one headache) and one subject was lost to follow-
up. Complete follow-up data were available for all 24
remaining subjects. Three of these subjects commenced
inhaled colistin therapy during the intervention period and
their data have been excluded, leaving 21 per protocol
subjects (15 female, mean  SD age 62.5  11 years, FEV1
percent predicted 65.5  26.2%). Pseudomonas aeruginosa
was cultured from sputum in 9 subjects, Haemophilus
influenzae in 3, Moraxella catarrhalis in 1, Aspergillus
fumigatus in 1 and normal flora in 7.
Erythromycin therapy was associated with highly signif-
icant, greater than 50% reductions in both co-primary
outcomes (see Table 1). No subject cultured new respira-
tory pathogens at the completion sample and no erythro-
mycin resistant organisms emerged during the study,
although 6 subjects who had initially cultured pathogens
(2 P. aeruginosa, 2 H. Influenzae, 1 M. catarrhalis, 1 A.
fumigatus) cultured normal flora only. Side-effects were
reported by only the two subjects who ceased the drug (one
nausea and one headache); liver function tests remained
normal in all subjects.
These uncontrolled data suggest that long-term, low-
dose erythromycin therapy may have a potent effect uponerythromycin periods* (Per protocol group, n Z 21).
Erythromycin 95% CI P value
2 (0e8) 1.5 to 3.5 <0.0001
21 (0e78) 18 to 40 <0.0001
0 (0e1) 0 to 1 0.0078
1 (0e8) 1 to 3 <0.0001
1.80(0.74) 0.29 to 0.12 0.39
representing the 12 months immediately preceding and following
948 D.J. Serisier, M.L. Martinexacerbation frequency in non-CF bronchiectasis subjects.
The reduction in exacerbations was clinically meaningful
and was consistent across patients with only one subject
showing an increase in exacerbation frequency. Further-
more, the magnitude of effect (50% reduction in exacer-
bation frequency) is similar to that previously reported for
azithromycin therapy.4e6
A number of recent reviews have highlighted the need
for RCT’s that address the efficacy of therapies, including
macrolides, in bronchiectasis.7,13 The current data
provided both powering data and strong impetus for
a prospective clinical study and we have subsequently
commenced a double-blind, placebo-controlled RCT, the
Bronchiectasis and Low-Dose Erythromycin Study (BLESS).
Sample size calculations for BLESS were based upon more
modest estimates of baseline exacerbation frequency12 and
treatment effect than the current study, showing that 98
subjects give 90% power to show a 28% reduction in annual
exacerbation frequency at the 5% significance level.
Numbers have been increased to allow for dropout.
The potential for development of antibiotic resistance
with long-termantibiotic therapy is a critical issue that needs
to be carefully weighed against potential benefits, notwith-
standing the lesser risk associated with erythromycin than
the long-acting macrolides. Seemungal et al found little
evidence of development of erythromycin resistance in
sputumpathogenswith 12months of erythromycin therapy in
COPD subjects.14 However the development of macrolide
resistance within identified respiratory pathogens is not the
greatest concern, particularly in bronchiectasis subjects
whose dominant respiratory pathogens are rarely constitu-
tively macrolide susceptible anyhow. Instead, the primary
risk of resistance induction with long-term antibiotic use
relates to commensal organisms, particularly oropharyngeal
streptococci, which can then be transmitted between indi-
viduals within the community with subsequent effects upon
population resistance. Hence, in the subsequent BLESS RCT,
macrolide susceptibility of oropharyngeal flora forms a key
outcome measure, performed using the methods described
by Malhotra-Kumar et al.9
The daily dose of erythromycin selected for the current
study (250 mgs of erythromycin base) is lower than that
described in prior studies in DPB (400e600 mg),15 COPD
(500 mgs)14 or bronchiectasis (1000 mgs).12 The current
data support the selection of this low-dose, which mini-
mises the potential for side-effects.
The exact mechanism/s by which macrolides exert
beneficial effects in CF and DPB are unclear. Of relevance
to the chronic suppurative airways diseases, demonstrated
effects include inhibition of neutrophil elastase,16 reduc-
tions in IL-8 expression and release from epithelial cells17,18
and attenuation of both mucin synthesis and mucus secre-
tion.19,20 However, human studies evaluating the potential
in vivo immunomodulatory mechanisms of action of mac-
rolides have been limited to evaluations of blood and
respiratory secretions and there is a need for more detailed
mechanistic data in humans. The BLESS study includes
a bronchoscopy study subgroup that will provide important
mechanistic and pathophysiologic data via endobronchial
biopsies. The current data are the catalyst for clinical
research that we hope will inform our understanding and
future management of not only non-CF bronchiectasis, butalso respiratory immunomodulatory therapy with macrolide
antibiotics.Conflict of interest statement
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